Creative Biolabs has been focusing on the development of high-quality in vitro diagnostic (IVD) antibodies for the diagnosis of a diversified battery of diseases, including autoimmune diseases, cancers, and infectious diseases. We offer antibodies that are developed against different biomarkers of rheumatoid arthritis, which can provide important information for the prognosis, diagnosis, and treatment of the disease. Particularly, 14-3-3 eta protein is a promising biomarker for the diagnosis and prognosis in rheumatoid arthritis patients.

Introduction of 14-3-3 Eta Protein

14-3-3 eta protein, which belongs to the 14-3-3 protein family, is responsible for regulating the signal transduction of cell signaling. Seven isotypes of 14-3-3 protein have been identified. They all share a highly conserved sequence and can interact with a number of intracellular proteins to mediate a series of regulation processes, such as cell metabolism, protein synthesis, trafficking, and transport. 14-3-3 eta protein has been shown to play significant roles in activating cell immune responses and regulating ligand activity as well as mediating the inflammatory cytokines in signaling cascades. Furthermore, 14-3-3 eta protein has been studied in a large number of patients with different types of diseases, including osteoarthritis, type 1 diabetes, Crohn's disease, and rheumatoid arthritis (RA).

14-3-3 Eta Protein as a Diagnostic Marker for RA

Studies have shown that the level of 14-3-3 eta protein is high in synovial fluid and the joint may be the potential source of 14-3-3 eta, suggesting that 14-3-3 eta protein can be associated with joint-related diseases. Meanwhile, recent researchers have demonstrated that serum concentrations of 14-3-3 eta protein are significantly higher in patients with RA and that 14-3-3 eta is related to the pathologic process of RA. Consequently, it has been regarded as a biomarker for the early diagnosis of RA. 14-3-3 eta detection should be beneficial to minimize joint damage to a large extent. In addition, various antibody-based immunoassays targeting 14-3-3 eta protein or its complements are also important to improve the sensitivity of RA diagnosis.

The main regulatory mechanism of 14-3-3 proteins participated in cellular processes.Fig.1 The main regulatory mechanism of 14-3-3 proteins participated in cellular processes. (Shi, L., 2019)

IVD Antibodies Targeting 14-3-3 Eta Protein

Recent studies have suggested that 14-3-3 eta is strongly associated with patients with RA. It is a significant marker for RA diagnosis and therapy. As a result, IVD antibodies against 14-3-3 eta can be developed to help the prognosis and diagnosis of RA, and to improve patient selection. At Creative Biolabs, we provide polyclonal, monoclonal, and recombinant antibody development services for diagnostic use. Moreover, these antibodies can be customized for the development of different immunoassay formats, including ELISAs, immunohistochemistry, western blot, and so on.

Creative Biolabs is a forward-looking research institute as well as a leading customized service provider in the field of IVD antibody development. Equipped with a team of professional scientists, we are capable of providing our clients with products and services with the best quality. We guarantee the finest results for our customers all over the world. If you are interested in our services, please contact us for more details.


  1. Shi, L., (2019). “14-3-3 Proteins: a window for a deeper understanding of fungal metabolism and development.” World J Microbiol Biotechnol, 35(2), 24.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.